CDH1 and breast carcinoma: A high level of miR-9 expression in TNBC patients is associated with EMT and breast cancer stem cell (BCSC) phenotypes, which directly target cadherin 1 (CDH1) to activate β-catenin and vascular endothelial growth factor (VEGF), leading to increased cell motility, invasiveness and tumor angiogenesis [68,69].